117 related articles for article (PubMed ID: 21570199)
1. Change in the growth rate of localized pancreatic adenocarcinoma in response to gemcitabine, bevacizumab, and radiation therapy on MDCT.
Rezai P; Yaghmai V; Tochetto SM; Galizia MS; Miller FH; Mulcahy MF; Small W
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):452-9. PubMed ID: 21570199
[TBL] [Abstract][Full Text] [Related]
2. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer.
Small W; Mulcahy MF; Rademaker A; Bentrem DJ; Benson AB; Weitner BB; Talamonti MS
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):476-82. PubMed ID: 20598452
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
Crane CH; Winter K; Regine WF; Safran H; Rich TA; Curran W; Wolff RA; Willett CG
J Clin Oncol; 2009 Sep; 27(25):4096-102. PubMed ID: 19636002
[TBL] [Abstract][Full Text] [Related]
5. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Watkins DJ; Starling N; Cunningham D; Thomas J; Webb J; Brown G; Barbachano Y; Oates J; Chau I
Eur J Cancer; 2014 May; 50(8):1422-9. PubMed ID: 24613126
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer.
Sahora K; Schindl M; Kuehrer I; Eisenhut A; Werba G; Brostjan C; Telek B; Ba'ssalamah A; Stift J; Schoppmann SF; Gnant M
Anticancer Res; 2014 May; 34(5):2377-84. PubMed ID: 24778046
[TBL] [Abstract][Full Text] [Related]
7. Tumor growth kinetics versus RECIST to assess response to locoregional therapy in breast cancer liver metastases.
Seyal AR; Parekh K; Velichko YS; Salem R; Yaghmai V
Acad Radiol; 2014 Aug; 21(8):950-7. PubMed ID: 24833565
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of cetuximab and gemcitabine in combination with radiation therapy: feasibility and efficacy in locally advanced pancreatic head cancer.
Fiore M; Trodella L; Valeri S; Borzomati D; Floreno B; Ippolito E; Trecca P; Trodella LE; D'Angelillo RM; Ramella S; Coppola R
Radiat Oncol; 2015 Dec; 10():255. PubMed ID: 26670587
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
Kindler HL; Friberg G; Singh DA; Locker G; Nattam S; Kozloff M; Taber DA; Karrison T; Dachman A; Stadler WM; Vokes EE
J Clin Oncol; 2005 Nov; 23(31):8033-40. PubMed ID: 16258101
[TBL] [Abstract][Full Text] [Related]
10. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX.
Vreeland TJ; McAllister F; Javadi S; Prakash LR; Fogelman DR; Ho L; Varadhachary G; Aloia TA; Vauthey JN; Lee JE; Kim MP; Katz MHG; Tzeng CD
Pancreas; 2019 Jul; 48(6):837-843. PubMed ID: 31210666
[TBL] [Abstract][Full Text] [Related]
11. Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer.
Sohal DP; Metz JM; Sun W; Giantonio BJ; Plastaras JP; Ginsberg G; Kochman ML; Teitelbaum UR; Harlacker K; Heitjan DF; Feldman MD; Drebin JA; O'Dwyer PJ
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1485-91. PubMed ID: 23532207
[TBL] [Abstract][Full Text] [Related]
12. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D
BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
Kullmann F; Hartmann A; Stöhr R; Messmann H; Dollinger MM; Trojan J; Fuchs M; Hollerbach S; Harder J; Troppmann M; Kutscheidt A; Endlicher E
Oncology; 2011; 81(1):3-8. PubMed ID: 21894049
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.
Crane CH; Varadhachary GR; Yordy JS; Staerkel GA; Javle MM; Safran H; Haque W; Hobbs BD; Krishnan S; Fleming JB; Das P; Lee JE; Abbruzzese JL; Wolff RA
J Clin Oncol; 2011 Aug; 29(22):3037-43. PubMed ID: 21709185
[TBL] [Abstract][Full Text] [Related]
15. Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.
Astsaturov IA; Meropol NJ; Alpaugh RK; Burtness BA; Cheng JD; McLaughlin S; Rogatko A; Xu Z; Watson JC; Weiner LM; Cohen SJ
Am J Clin Oncol; 2011 Feb; 34(1):70-5. PubMed ID: 20458210
[TBL] [Abstract][Full Text] [Related]
16. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
Ko AH; Venook AP; Bergsland EK; Kelley RK; Korn WM; Dito E; Schillinger B; Scott J; Hwang J; Tempero MA
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1051-7. PubMed ID: 20130876
[TBL] [Abstract][Full Text] [Related]
18. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab.
Van Loon K; Espinoza AM; Fogelman DR; Wolff RA; Javle MM; Iyer RV; Picozzi VJ; Martin LK; Bekaii-Saab T; Tempero MA; Foster NR; Kim GP; Ko AH
Pancreas; 2014 Apr; 43(3):343-9. PubMed ID: 24622062
[TBL] [Abstract][Full Text] [Related]
19. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.
Ko AH; Youssoufian H; Gurtler J; Dicke K; Kayaleh O; Lenz HJ; Keaton M; Katz T; Ballal S; Rowinsky EK
Invest New Drugs; 2012 Aug; 30(4):1597-606. PubMed ID: 21629990
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
